1 / 29

Tomer M. Mark Department of Medicine, Division of Hematology / Oncology

Case 2: Transplant-eligible patient with newly diagnosed myeloma – would you recommend transplant, and if so, what induction regimen?. Tomer M. Mark Department of Medicine, Division of Hematology / Oncology Weill-Cornell Medical College / New York Presbyterian Hospital, New York, NY, USA

masato
Télécharger la présentation

Tomer M. Mark Department of Medicine, Division of Hematology / Oncology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Case 2: Transplant-eligible patient with newly diagnosed myeloma – would you recommend transplant, and if so, what induction regimen? Tomer M. Mark Department of Medicine, Division of Hematology / Oncology Weill-Cornell Medical College / New York Presbyterian Hospital, New York, NY, USA Lymphoma & Myeloma 2013

  2. Disclosures Research Funding: CelgeneInc.; Onyx Inc. Speakers Bureau: Celgene Corp; Millennium Inc.; Onyx Inc. Membership on an entity's advisory committees: Celgene Corp., Millennium Inc. Off-label usage of bortezomib, lenalidomide, and carfilzomib are discussed

  3. Case History • A 45 year-old male with a history of obesity and type-2 diabetes, “diet-controlled”, develops back pain after moving furniture • When the back pain doesn’t relent after 3 weeks, he sees his PMD who advises NSAID use • There is minimal relief after taking 800mg ibuprofen TID. He sees his PMD again the following week and a plain film of the spine is ordered

  4. History • Multiple lytic lesions of the lumbar spine are noted • The PMD refers to an oncologist who orders bloodwork, a 24 hour urine, skeletal survey, and performs a bone marrow biopsy.

  5. Medical History PMHx: • Diet-controlled diabetes • Episode of Legionella pneumonia Med: • Ibuprofen 800mg prn SHx: • Works as a hospital administrator • Former tobacco use: 10 pack years, quit 15 years ago • Social EtOH, no illicit drug use • FHx: • Mother: Crohn’s disease • Sister: breast cancer • Uncle: colon cancer ROS: • +back pain PE GEN: middle-aged male, NAD HEENT: PERRL, EOMI, anicteric sclerae NECK: no masses, nl carotid upstroke CV: nl S1/S2, RRR, no m/r/g PULM: CTAB ABD: soft, NT/ND, +bowel sounds EXT: no c/c/e MSK: no spinal tenderness on palpation, he lies down on the exam table with great difficulty.

  6. Diagnostic Tests • Skeletal survey: multiple lytic lesions in the T, L-spine, cranium, pelvis, and R prox femur • Bone Marrow Aspirate: 86% plasma cells with atypical features, kappa-light chain restricted • Karyotype: 46 XY • FISH: 2/20 cells + del13q

  7. 9.8 8.3 236 29.4 140 113 22 131 3.7 19 1.4 Diagnostic Tests Laboratory Results: Serum Protein Electrophoresis: Decreased amounts of gamma globulins with a monoclonal spike- 3.2 g/dL Immunofixation / Quantitative Immunoglobulins: IgM: <4 mg/dL; IgA: 12 mg/dL; IgG: 4300 mg/dL 24 hr Urine Electropheresis and Immunofixation: Total Protein: 2.08g/day 10% albumin 90% kappa free light chain Serum Free Light Chain Assay: Kappa FLC: 1540 mg/dL Lambda 0.67: mg/dL Kappa/Lambda: 2300 Albumin: 3.6 Calcium 8.9 T. Bili: 0.8 Alk Phos: 57 AST: 38 ALT: 35 LDH: 190 2M: 3.8 CRP: 0.54

  8. Summary • 45 year-old male with history of hyperglycemia and newly diagnosed SD Stage 3a, ISS Stage 2, IgG-kappa MM, with extensive skeletal involvement and mild renal insufficiency.

  9. Is a Stem Cell Transplant Recommended? • Stem cell transplant has a OS benefit • Caveat: data is old • Stem cell transplant deepens treatment response • Does a deeper response post-transplant lead to longer OS? • What if pt is in CR prior to transplant?

  10. ASCT vs. Conventional Chemotherapy § Significant P value Attal M et al. N Engl J Med. 1996;335:91. Fermand J et al. Blood. 1998;92:3131. Bladé et al. Hematol J. 2001;2:272 Child JA et al. N Engl J Med. 2003;348:1875.

  11. Does Transplant Timing Matter? Fermand J et al. Blood 1998;92:3131-3136

  12. Does Consolidation With ASCT Improve Outcomes?

  13. Impact of Response To Induction Therapy Lahuerta, J. J. et al. J Clin Oncol 26:5775-5782 2008

  14. Significance of Depth of Response Lahuerta, J. J. et al. J ClinOncol 26:5775-5782 2008

  15. “Upgraders” do better Improvement for PR to nCR or CR post transplant increases OS Significance of Continued Response to HDT Lahuerta, J. J. et al. J ClinOncol 26:5775-5782 2008

  16. Initial Response to Induction Conventional Chemotherapy does not Impact Transplant Benefit • Singhal et al, 2002. Survival post C-VAMP induction ASCT had no correlation with C-VAMP response. • Kumar et al, 2004. 50 patients with primary refractory MM (mostly VAD) compared to 100 with chemosensitive disease pre-ASCT. 20% vs. 35% CR post transplant (P = 0.06). 1-year PFS 70% vs. 83% (P=0.65). • Alexanian et al, 1995. MM resistant to VAD or high-dose dex quadrupled OS compared to matched controls.

  17. Initial Response to Induction Chemotherapy does not Impact Transplant Benefit Important factors on MV analysis: PCLI >1, CR, abnormal cytogenetics, serum M-protein, circulating PC at harvest. Kumar et al. Bone Marrow Transplantation. 2004. 34: 161-167.

  18. Initial Response to Induction Chemotherapy does not Impact Transplant Benefit Is this still true in the era of novel agents?

  19. Impact of Response Failure To Induction with Immunomodulators • N = 286 • PFS from Day 0 of transplantation • Plateau (232), Refractory (29), Relapse (25) • Thal/Dex (189), Len/Dex (97) • Medians: 22.1 m (plateau), 15.1 (refractory), 12.0 (relapse) on induction therapy Gertz, M. A. et al. Blood 2010;115:2348-2353

  20. Impact of Response Failure To Induction with Immunomodulators • Overall survival from Day 0 of transplant • Med OS 73.5 (plateau), 32.7 (refractory), 23.8m (relapse on tx) Gertz, M. A. et al. Blood 2010;115:2348-2353

  21. Factors That Impact Transplant Success with ImmunomodulatorInduction Gertz, M. A. et al. Blood 2010;115:2348-2353

  22. Multiple Studies Comparing Novel Agents to CC followed by ASCT

  23. Do You Need a Transplant if You Achieve CR With Induction Therapy? ASCT within 1 yr Chemo-alone Wang et al., 2010, Bone Marrow Transplant, 45, 498-504

  24. Do You Need ASCT if You Continue Induction Instead? P=0.64 • No transplant: 42 patients, 15 events. Median EFS not reached. • 3-year EFS = 65% (95% CI = 47.6%, 77.9%) • Transplant: 29 patients, 14 events. Median EFS = 37.3 months. • 3-year EFS 50.3% (95% CI = 27.2%, 69.5%

  25. Conclusions • Combinations of novel agents lead to deeper responses pre-transplant • Deeper responses pre-transplant translate to better responses post transplant • ASCT is supplementary to induction, not a substitute. • ASCT is a tool to achieve high CR and prolonged PFS • Lack of difference in OS is a reflection on efficacy of salvage tx. • Achievement of CR prior to transplant gives an equal outcome to CR post-transplant • MRD detection may change this conclusion

  26. What Induction Therapy Should be Used? • What is More Important? a) Choice of Agent for Induction b) Response attained in Induction

  27. Can’t See The Forest for The Trees

  28. 73 74 61 76 • Niesvizky et al Blood, 111, 1101-1109; 2008. • Richardson et al. ASH 2008, Abstract 92 3. Reeder et al, Leukemia2009, 23:1337-41 4. Bensinger et al. ASH 2008, Abstract 94

  29. Thank You

More Related